Choriocarcinoma is a rare, fast-growing cancer that develops from the cells that normally form the placenta during pregnancy. It is highly invasive and builds an extensive blood supply quickly, which means it can spread to distant organs. Despite its aggressive nature, choriocarcinoma is one of the most treatable solid cancers, with survival rates approaching 100% for low-risk cases and around 94% even for high-risk disease.
How Choriocarcinoma Develops
During a normal pregnancy, specialized cells called trophoblasts attach the fertilized egg to the uterine wall and eventually form the placenta. In choriocarcinoma, these trophoblast cells grow uncontrollably, forming a tumor made up of abnormal tissue without the finger-like projections (villi) seen in a healthy placenta. Because trophoblasts are naturally designed to invade uterine tissue and tap into blood vessels, a cancer arising from them is especially prone to spreading through the bloodstream.
Gestational vs. Non-Gestational Types
Choriocarcinoma comes in two main forms. The gestational type, by far the more common one, develops after some kind of pregnancy event. Roughly 50% of gestational cases follow a molar pregnancy (a fertilized egg that develops into an abnormal mass instead of a viable embryo). About 25% occur after a normal term pregnancy, and the remaining 25% follow miscarriages, ectopic pregnancies, or other pregnancy-related events.
Non-gestational choriocarcinoma is much rarer. It arises from germ cells, the same type of cells that produce eggs and sperm, and can appear in the ovaries, testes, or other midline locations like the chest or brain. It sometimes also develops alongside another aggressive cancer. Distinguishing between the two types matters because they are staged differently and may require different treatment approaches. In women of reproductive age, telling them apart can be particularly difficult.
Common Symptoms
The most frequent early sign of gestational choriocarcinoma is abnormal vaginal bleeding that persists weeks to months after a pregnancy, delivery, or molar pregnancy evacuation. The bleeding may be irregular, heavier than a normal period, or occur long after you would expect postpartum bleeding to stop.
Because choriocarcinoma spreads through the bloodstream so readily, symptoms from distant sites are sometimes the first clue. In a systematic review of unusual presentations, cardiopulmonary complaints (shortness of breath, coughing, chest pain) were the most common at about 21% of cases. Gastrointestinal symptoms like abdominal pain or internal bleeding accounted for roughly 18%, and neurological symptoms such as headaches, seizures, or vision changes made up about 18% as well. Lung metastases are the most frequent distant spread, but the tumor can also reach the liver, brain, spleen, or kidneys.
How It Is Diagnosed
A key diagnostic marker is hCG, the same hormone measured in a pregnancy test. Choriocarcinoma causes extremely high hCG levels in the blood, typically appearing one to three months after a delivery, though it can surface weeks to years later. If you have a persistently elevated or rising hCG level after a pregnancy event and you are not pregnant again, that is a major red flag.
Imaging studies, usually ultrasound of the uterus followed by CT scans of the chest, abdomen, and brain, help determine whether the cancer has spread. In many cases, a tissue biopsy is not needed because the combination of pregnancy history, sky-high hCG, and characteristic imaging findings is enough to make the diagnosis.
Staging and Risk Classification
Choriocarcinoma is staged using the FIGO system, which has four stages based on how far the tumor has spread:
- Stage I: Cancer is confined to the uterus.
- Stage II: Cancer has spread to nearby genital structures, such as the vagina or fallopian tubes.
- Stage III: Cancer has reached the lungs, with or without genital tract involvement.
- Stage IV: Cancer has spread to other distant sites like the brain, liver, kidneys, or gastrointestinal tract.
Alongside the anatomical stage, doctors calculate a prognostic risk score using eight factors: your age, the type of pregnancy that preceded the cancer, how many months have passed since that pregnancy, your hCG level before treatment, tumor size, where the cancer has spread, the number of metastases, and whether any previous chemotherapy has already failed. Each factor receives a point value, and the total score determines whether you fall into the low-risk or high-risk category. A score of 6 or below is considered low risk, while 7 or above is high risk. This distinction directly shapes the treatment plan.
Treatment
Choriocarcinoma is remarkably sensitive to chemotherapy, which is why cure rates are so high even when the cancer has spread. Low-risk patients typically receive a single chemotherapy drug given in repeated cycles. Treatment continues until hCG levels drop to normal and then for a few additional cycles to make sure no cancer cells remain.
High-risk patients receive multi-drug chemotherapy regimens that combine several agents given on alternating schedules. These are more intensive but still highly effective. For the small percentage of patients who do not respond to first-line treatment, alternative drug combinations or surgical removal of resistant tumor sites may be added.
Surgery, most often a hysterectomy, plays a limited role. It may be recommended for patients who have completed childbearing and have disease confined to the uterus, or in emergency situations involving heavy bleeding. For most patients, chemotherapy alone is the primary treatment.
Survival and Outlook
The prognosis for choriocarcinoma is among the best of any cancer. Low-risk gestational choriocarcinoma has a survival rate near 100%. Even high-risk cases, including those that have spread to the lungs or other organs, carry a survival rate of about 94%. The key to these outcomes is the cancer’s exceptional sensitivity to chemotherapy and the ability to track treatment response precisely through hCG blood levels. As hCG drops toward zero, doctors can confirm the cancer is responding.
Fertility After Treatment
Because choriocarcinoma often affects women during their reproductive years, fertility is a major concern. The good news is that most women treated with chemotherapy alone retain the ability to become pregnant afterward. Guidelines generally recommend waiting at least 12 months after hCG levels return to normal before trying to conceive, giving the body time to recover and ensuring no relapse occurs during the monitoring period. During any subsequent pregnancy, hCG will naturally rise, so having a confirmed normal baseline beforehand is important. After a future delivery, hCG levels are typically rechecked to rule out recurrence.